-

05:33:09 AM

AUTL Stock News

AUTL - Autolus Therapeutics plc

05/12/22 10:51 AM

Nasdaq : AUTL

conferencesclinical trial

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma - AUTO1/22: oral presentation on initial experience in r/r pediatric B-cell acute lymphoblastic leukemia - obe-cel: poster presentation in r/r primary CNS lymphoma - obe-cel: poster presentation in r/r

RHEA-AI

neutral

05/05/22 7:00 AM

Nasdaq : AUTL

earnings

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

RHEA-AI

neutral

05/02/22 4:31 PM

Nasdaq : AUTL

conferences

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies,

RHEA-AI

neutral

04/25/22 7:01 AM

Nasdaq : AUTL

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced

RHEA-AI

neutral

04/25/22 7:00 AM

Nasdaq : AUTL

conferencesearnings

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2022 financial results and operational highlights before

RHEA-AI

neutral

03/31/22 7:00 AM

Nasdaq : AUTL

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that the European Medicines Agency (EMA) has granted obe-cel, Autolus’ leading CAR T clinical

RHEA-AI

very positive

03/29/22 7:00 AM

Nasdaq : AUTL

conferences

Autolus Therapeutics to Participate in Conferences During April 2022

RHEA-AI

neutral

03/10/22 7:00 AM

Nasdaq : AUTL

earnings

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and

RHEA-AI

neutral

03/03/22 7:00 AM

Nasdaq : AUTL

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

- Publication describing a novel technology that provides for very low levels of expression of one programming module relative to another programming module 1 - Method for expressing stable low levels of a toxic gene - technology deployed in Autolus’ approach for the treatment of solid tumors -

RHEA-AI

neutral

02/21/22 7:00 AM

Nasdaq : AUTL

conferencesearnings

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2021 financial results and operational

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

AUTL Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.autolus.com
Security nameAutolus Therapeutics plc - ADR
Issue typead
SectorManufacturing
Sic code2836
Employees2021
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressScale Space Building
Address2White City
StateLondon
City58 Wood Lane
ZipW12 7RZ
CountryUnited Kingdom
Phone442038296230

About Autolus Therapeutics plc

Autolus Therapeutics plcis a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.